Physician profile
Murray J Propes
NPI 1942495874
$9,021.88
in general payments reported to CMS, 2019-2025
42 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 89% of Phlebology providers received nationally (typical 2025 total: $141).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.42 · 2020: $219 · 2021: $1,388 · 2022: $1,964 · 2023: $2,012 · 2024: $1,743 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,419 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,419.12 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,362.75 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,152.25 | 2020-2025 | |
| Pfizer INC. | $1,102.36 | 2021-2025 | |
| Amgen INC. | $990.12 | 2020-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $679.21 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $624.41 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $424.90 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $275.69 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $219.21 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.50 | 2022-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $182.79 | 2023-2025 | Spravato |
| Amneal Pharmaceuticals LLC | $165.71 | 2022-2025 | Unithroid |
| Corcept Therapeutics | $152.43 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $130.92 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.05 | 2021-2023 | Eliquis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Propes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.